[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-mold-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-mold-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100648649","safety-and-efficacy-of-liposomal-amphotericin-b-for-patients-with-invasive-mold-diseases-in-liver-transplant-recipients-100648649",false,"NCT07725874","Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients","Inclusion Criteria:\n\nPatients aged ≥12 years. Liver transplant recipients. Proven or probable invasive mold disease (IMD) according to the 2020 EORTC\u002FMSGERC criteria.\n\nHave received at least one dose of liposomal amphotericin B (AmBisome) or voriconazole.\n\nExclusion Criteria:\n\nHistory of invasive mold disease previously treated with amphotericin B for more than 5 days.\n\nDocumented hypersensitivity or allergy to amphotericin B formulations. Sequential Organ Failure Assessment (SOFA) score \\>15. Expected survival \\\u003C72 hours. Pregnant or breastfeeding. Patients who, in the investigator's judgment, are unable to complete the study treatment or follow the study protocol.\n\nRecipients of combined organ transplantation or multivisceral transplantation.","ALL","12 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","Invasive mold diseases (IMD) carry extremely high mortality rates in liver transplant recipients (aspergillosis prevalence \\~1.8%, mortality 60%-90%; mucormycosis prevalence \\~2%, mortality 38%-95%). Guidelines emphasize early antifungal therapy: liposomal amphotericin B (L-AmB) is the first-line choice in liver insufficiency; voriconazole remains the gold standard for aspergillosis (but ineffective against mucormycosis), yet its use is limited by significant drug-drug interactions-requiring a 50%-60% dose reduction of calcineurin inhibitors and contraindicated with sirolimus-thereby increasing the risk of graft rejection. Currently, no head-to-head clinical trials compare voriconazole and L-AmB in liver transplant recipients with IMD. Therefore, a prospective real-world study is planned to generate robust data to support updates to international or Chinese guidelines.",[25],"Invasive Mold Diseases","NOT_YET_RECRUITING","2026-07-22",{"date":29,"type":30},"2026-07-24","ACTUAL",{"date":32,"type":19},"2026-08-08",{"date":34,"type":19},"2028-08-15",{"name":36,"class":37},"Beijing Friendship Hospital","OTHER"]